* CASI Pharmaceuticals Inc CASI.OQ CASI.O is expected
to show
a rise in quarterly revenue when it reports results on May 12.
* The Rockville Maryland-based company is expected to
report a
61.0% increase in revenue to $9.233 million from $5.74 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for CASI
Pharmaceuticals Inc
is for a loss of 9 cents per share. For the same quarter last
year, the company reported a loss of 11 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $4, above its last closing price
of $0.36.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.06 -0.04 Beat 29.4
Sep. 30 2021 -0.06 -0.05 -0.07 Missed -27.3
Jun. 30 2021 -0.08 -0.07 -0.05 Beat 31
Mar. 31 2021 -0.06 -0.06 -0.11 Missed -83.3
Dec. -0.07 -0.12 Missed -71.4
31 2020
Sep. 30 2020 -0.06 -0.05 -0.14 Missed -154.5
Jun. 30 2020 -0.08 -0.08 -0.07 Beat 12.5
Mar. 31 2020 -0.11 -0.09 Beat 18.2
This summary was machine generated May 10 at 18:32 GMT. All
figures in US dollars unless otherwise stated